Table 2.
ROC Analysis Performed on Biometrics for LGG, HGG, and MET With Sensitivity/Specificity/Cutoff Value/AUC/P-value
| Group and Biometric | Sensitivity (%) | Specificity (%) | Cutoff Value | AUC (95% CI) | P-Value < |
|---|---|---|---|---|---|
| HGG/LGG | |||||
| tLip/tChoa | 83.3 | 100 | 2.35 | 0.905 (0.746-1.00) | .004 |
| Ins/tChoa | 100 | 75 | 1.61 | 0.905 (0.767-1.00) | .004 |
| Combined Biometricsa | 100 | 100 | 0.499b | 1.00 (1.00-1.00) | .001 |
| HGG/MET | |||||
| tCr/tChoc | 77.8 | 76.7 | 2.65 | 0.824 (0.647-1.00) | .013 |
| tCho/tCrd | 75 | 84.6 | 0.37 | 0.788 (0.567-1.00) | .030 |
| NAA/tChod | 75 | 84.6 | 0.80 | 0.817 (0.634-1.00) | .017 |
| Combined Biometricsc,d | 100 | 81.8 | 0.311b | 0.935 (0.825-1.00) | .002 |
| LGG/MET | |||||
| tLip/tChoe | 100 | 100 | 3.59 | 1.00 (1.00-1.00) | .001 |
| Ins/tChoe | 85.7 | 100 | 1.69 | 0.984 (0.935-1.00) | .001 |
| Combined Biometricse | 100 | 100 | 0.50b | 1.00 (1.00-1.00) | .001 |
Significance level set at P-value <.05:
aComparing non-enhancing hypo intense volume on T1-MPRAGE (100% anticipated tumor tissue) for LGG with contrast enhancing tissue for HGG;
bProbability cut-off value generated by regression model;
cComparing edematous tissue between HGG and MET;
dComparing ipsilateral normal appearing white matter in HGG and MET;
eComparing NE hypointense volume on T1-MPRAGE (100% anticipated tumor tissue) for LGG with CE tissue for MET.